---
schema_version: "secwatch.filing_event.v1"
accession: "0001601830-26-000064"
form_type: "8-K"
ticker: "RXRX"
cik: "0001601830"
company_name: "RECURSION PHARMACEUTICALS, INC."
filed_at: "2026-04-30T23:59:59+00:00"
generated_at: "2026-05-15T00:53:42.438896+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.4
calibrated_materiality_score: 0.4
confidence: "high"
source: SEC EDGAR
---

# Recursion founder & Chair Chris Gibson will not stand for re-election; to become advisor

## Summary
- Chris Gibson, Ph.D., founder and Chair, will not seek re-election at 2026 Annual Meeting (June 2026).
- He will continue as Chair until term ends, then serve as strategic advisor to the company.
- Gibson stated decision not due to any disagreement with Recursion on operations, policies, or practices.
- CEO Najat Khan thanked Gibson, emphasizing continuity, pipeline progress, and long-term value creation.

## SEC filing metadata
- accession: 0001601830-26-000064
- form_type: 8-K
- ticker: RXRX
- cik: 0001601830
- company_name: RECURSION PHARMACEUTICALS, INC.
- filed_at: 2026-04-30T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.4
- calibrated_materiality_score: 0.4
- confidence: high
- sec_items: 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1601830/000160183026000064/0001601830-26-000064-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1601830/000160183026000064/rxrx-20260428.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001601830-26-000064
- JSON: https://secwatch.observer/filing/0001601830-26-000064.json
- Plain text: https://secwatch.observer/filing/0001601830-26-000064.txt

## Source-grounded claims
- claim_id: bb1e1b4d0a
  claim: Christopher Gibson departed as Chair of the Board of Directors at RECURSION PHARMACEUTICALS, INC..
  evidence_excerpt: On April 28, 2026, Christopher Gibson, Ph.D., Chair of the Board of Directors (the “Board”) of Recursion Pharmaceuticals, Inc. (the “Company”) and a member of the Research and Development Committee, Technology Committee, and the Corporate Social Responsibility Committee of the Board, informed the Company that he will not stand for re-election to the Board as a Class II Director at the 2026 Annual Meeting of Stockholders (the “2026 Annual Meeting”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1601830/000160183026000064/0001601830-26-000064-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.